Biogen Idec's (NASDAQ:BIIB) Tecfidera wasn't the first oral multiple sclerosis drug, but is sure has gotten off to a much faster start than Novartis' (NYSE:NVS) Gilenya, which was approved by the FDA in 2010 and Sanofi's (NYSE:SNY) Aubagio, which was approved in 2012.
In its third quarter on the market, Biogen registered nearly $400 million in sales, putting it well on its way to achieving blockbuster status. It's not hard to see Tecfidera catching more established injected drugs such as Teva Pharmaceuticals' Copaxone and Biogen Idec's own Avonex.
In the following video, Fool contributor Brian Orelli and health-care bureau chief Max Macaluso discuss why Biogen Idec got off to such a quick start where Novartis and Sanofi couldn't.
Looking for the next big thing
Every investor wants to get in on revolutionary ideas like Tecfidera before they hit it big. The problem is, most investors don't understand the key to investing in hyper-growth markets. The real trick is to find a small-cap "pure play" and then watch as it grows in explosive fashion with its industry. Our expert team of equity analysts has identified one stock that's poised to produce rocket-ship returns with the next $14.4 trillion industry. Click here to get the full story in this eye-opening report.
Brian Orelli and Max Macaluso, Ph.D., have no position in any stocks mentioned. The Motley Fool recommends Teva Pharmaceutical Industries. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.